Charles Schwab Investment Management Inc. Acquires 6,418 Shares of Simulations Plus, Inc. (NASDAQ:SLP)

Charles Schwab Investment Management Inc. increased its stake in Simulations Plus, Inc. (NASDAQ:SLP) by 4.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 143,253 shares of the technology company’s stock after acquiring an additional 6,418 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.71% of Simulations Plus worth $3,995,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Jones Financial Companies Lllp boosted its holdings in Simulations Plus by 53.6% in the fourth quarter. Jones Financial Companies Lllp now owns 1,223 shares of the technology company’s stock worth $34,000 after acquiring an additional 427 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Simulations Plus during the third quarter worth approximately $59,000. US Bancorp DE lifted its holdings in shares of Simulations Plus by 14.3% in the 4th quarter. US Bancorp DE now owns 5,687 shares of the technology company’s stock worth $159,000 after purchasing an additional 713 shares in the last quarter. Pitcairn Co. grew its position in Simulations Plus by 9.1% in the 3rd quarter. Pitcairn Co. now owns 6,599 shares of the technology company’s stock valued at $211,000 after purchasing an additional 549 shares during the period. Finally, Olympiad Research LP bought a new stake in Simulations Plus during the 4th quarter valued at $211,000. Institutional investors and hedge funds own 78.08% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on SLP shares. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, January 8th. KeyCorp raised their price target on shares of Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Simulations Plus has a consensus rating of “Moderate Buy” and an average target price of $49.40.

Simulations Plus Price Performance

NASDAQ SLP opened at $24.00 on Thursday. The company has a fifty day moving average price of $31.03 and a 200-day moving average price of $30.68. The firm has a market cap of $482.21 million, a price-to-earnings ratio of 60.00 and a beta of 0.89. Simulations Plus, Inc. has a 1 year low of $23.73 and a 1 year high of $51.22.

Insider Buying and Selling

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total value of $678,200.00. Following the completion of the transaction, the director now owns 3,402,584 shares in the company, valued at $115,381,623.44. This represents a 0.58 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 19.40% of the stock is owned by corporate insiders.

Simulations Plus Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.